[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hao Yonggang\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":71},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":5},"100658246","early-anticoagulation-therapy-after-endovascular-treatment-for-acute-ischemic-stroke-with-atrial-fibrillation-100658246",false,"NCT07849777","Early Anticoagulation Therapy After Endovascular Treatment for Acute Ischemic Stroke With Atrial Fibrillation","EATAF","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Symptom onset within 24 hours before enrollment.\n3. A confirmed diagnosis of acute anterior circulation ischemic stroke.\n4. A baseline NIHSS score ≥6 at admission.\n5. An Alberta Stroke Program Early CT Score (ASPECTS) ≥6.\n6. Computed tomography angiography (CTA), magnetic resonance angiography (MRA), or digital subtraction angiography (DSA) confirming occlusion of the intracranial internal carotid artery (ICA) or the M1\u002FM2 segment of the middle cerebral artery (MCA), with the patient scheduled to undergo EVT.\n7. Computed tomography (CT) or magnetic resonance imaging (MRI) performed within 24 hours after EVT demonstrating no evidence of hemorrhagic transformation.\n8. Documentation of paroxysmal, persistent, or permanent atrial fibrillation based on electrocardiography or previous medical records.\n9. Written informed consent provided by the patient or a legally authorized representative.\n\nExclusion Criteria:\n\n1. Pre-stroke modified Rankin Scale (mRS) score \\>2.\n2. Valvular atrial fibrillation.\n3. Known hypersensitivity to anticoagulants or any other contraindication to anticoagulant therapy.\n4. Presence of systemic bleeding disorders, coagulopathy, or a platelet count \\\u003C100 × 10⁹\u002FL.\n5. Concomitant use of azole antifungal agents, HIV protease inhibitors, or strong CYP3A4 inducers.\n6. Presence of intracranial space-occupying lesions, including intracranial tumors or cerebral vascular malformations.\n7. History of major trauma or major surgery within 1 month before stroke onset.\n8. Evidence of active bleeding within 1 month before stroke onset, including but not limited to gastrointestinal bleeding or genitourinary bleeding.\n9. Cerebral amyloid angiopathy.\n10. Severe hepatic or renal impairment, or receipt of dialysis for any cause. Severe hepatic impairment is defined as alanine aminotransferase (ALT) \\>3 times the upper limit of normal (ULN) or aspartate aminotransferase (AST) \\>3× ULN. Severe renal impairment is defined as serum creatinine \\>3.0 mg\u002FdL (265.2 μmol\u002FL) or an estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73 m².\n11. Any terminal illness with an expected life expectancy of less than 6 months.\n12. Breastfeeding women.\n13. Participation in another interventional clinical trial within the previous 3 months.\n14. Any other condition that, in the investigator's judgment, would make the participant unsuitable for the study or interfere with study participation or completion, including but not limited to psychiatric disorders, cognitive or emotional impairment, or physical conditions that preclude adherence to study procedures or follow-up.","ALL","18 Years",{"count":19,"type":20},474,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to learn whether starting a direct oral anticoagulant (DOAC) early after endovascular treatment works to improve outcomes in patients with ischemic stroke related to atrial fibrillation. It will also learn about the safety of early DOAC treatment. The main question it aims to answer is:\n\n\\- Does starting DOAC treatment 24 hours after endovascular treatment improve outcomes at 3 months compared with starting it 5 days after randomization?\n\nResearchers will compare early DOAC treatment (started 24 hours after the procedure) with delayed DOAC treatment (started 5 days after randomization) to see if early treatment works better.\n\nParticipants will:\n\n* Have atrial fibrillation-related acute ischemic stroke caused by a large vessel blockage in the front part of the brain, within 24 hours of symptom onset\n* Be randomly assigned to one of two groups after endovascular treatment: early DOAC treatment or delayed DOAC treatment\n* Take DOACs starting 24 hours after the procedure (early group) or 5 days after randomization (delayed group)\n* Be followed up for 3 months to check their recovery and any medical problems",[26,27],"Stroke","Atrial Fibrillation (AF)",[29,30,31,32,33],"stroke","endovascular thrombectomy","atrial fibrillation","randomised controlled trial","direct oral anticoagulation","NOT_YET_RECRUITING","2026-10-06",{"date":37,"type":38},"2026-10-07","ACTUAL",{"date":40,"type":20},"2026-09-30",{"date":42,"type":20},"2029-09-30",{"name":44,"class":45},"Hao Yonggang","OTHER",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},"100619895","intensive-versus-conventional-blood-pressure-control-following-stroke-thrombectomy-100619895","NCT07350564","Intensive Versus Conventional Blood Pressure Control Following Stroke Thrombectomy","Intensive Blood Pressure Control After Endovascular Thrombectomy for Acute Embolic Stroke (INTENSE): a Multicentre, Open-label, Blinded-endpoint, Randomised Controlled Trial","INTENSE","Inclusion Criteria:\n\n* Age ≥ 18 years\n* To receive endovascular thrombectomy \\\u003C24 hours after the onset of symptoms\n* Diagnosed with acute anterior circulation ischemic stroke\n* National Institutes of Health Stroke Scale (NIHSS) score ≤ 30;\n* Alberta Stroke Program Early CT Score (ASPECTS) ≥ 6\n* Computed Tomography Angiography (CTA), Magnetic Resonance Angiography (MRA), or Digital Subtraction Angiography (DSA) confirming occlusion of the intracranial internal carotid artery or M1\u002FM2 segment of the middle cerebral artery\n* Successful recanalization of the occluded vessel without in-situ or proximal stenosis (modified Treatment in Cerebral Infarction, mTICI ≥ 2b)\n* Sustained elevated systolic blood pressure (≥140 mmHg for at least two consecutive measurements, separated by \\>10 minutes) within 3 hours of reperfusion\n* Written informed consent provided by the patient or their legal representative\n\nExclusion Criteria:\n\n* Pre-existing stroke disability defined by a modified Rankin score (mRS) \\>2\n* Unlikely to benefit from or tolerate endovascular thrombectomy, such as severe allergic reaction to contrast agents\n* Failure to achieve mTICI ≥ 2b with endovascular intervention, or presence of in situ or proximal vascular stenosis\n* Patients with contraindications for the use of antihypertensive medications, such as allergy to components\n* Intracranial space-occupying lesions, including brain tumors and vascular malformations\n* Patients with severe liver or renal dysfunction, or those receiving dialysis (severe liver dysfunction is defined as alanine aminotransferase \\[ALT\\] \\> 3 times the upper limit of normal or aspartate aminotransferase \\[AST\\] \\> 3 times the upper limit of normal; severe renal dysfunction is defined as serum creatinine \\> 3.0 mg\u002FdL \\[265.2 μmol\u002FL\\] or glomerular filtration rate \\[GFR\\] \\\u003C 30 mL\u002Fmin\u002F1.73 m²)\n* Serious illness with life expectancy of \\\u003C6 months\n* Lactating women\n* Participation in other interventional clinical trials within the past 3 months;\n* Any other conditions that render patients unsuitable for participation in this study or unable to complete the study process, such as psychiatric disorders, cognitive or emotional impairments, or physical conditions that hinder compliance with study procedures and follow-up",{"count":55,"type":20},910,[23],"This clinical trial aims to investigate the safety and efficacy of intensive blood pressure lowering after successful reperfusion with thrombectomy in patients with acute anterior circulation large artery occlusive stroke. The main questions it aims to answer are:\n\nWhat is the optimal blood pressure range after revascularization with thrombectomy in patients with cerebral embolism? Can intensive blood pressure lowering improve outcomes in cerebral embolism patients following thrombectomy?\n\nParticipants will be randomly assigned to either the intervention group, which receives stricter blood pressure control (systolic blood pressure target \\\u003C120 mmHg), or the control group, which follows a conventional blood pressure management approach (systolic blood pressure target 140-180 mmHg). Outcomes will be assessed during a 3-month follow-up period.",[26],[29,30,60,32],"blood pressure","RECRUITING","2026-01-11",{"date":64,"type":38},"2026-01-20",{"date":66,"type":38},"2025-11-01",{"date":68,"type":20},"2028-12-31",{"name":44,"class":45},1,""]